Axogen (FRA:LT3) Cyclically Adjusted Revenue per Share: €2.90 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LT3 Axogen Inc FRA:LT3
64 GF Score
Price €35.11
GF Value €13.34
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Axogen Cyclically Adjusted Revenue per Share?

Axogen FRA:LT3 +3.20% 64 Cyclically Adjusted Revenue per Share is €2.90 as of Mar. 2026. GuruFocus rates FRA:LT3 with a GF Score™ of 64/100 and a GF Value™ of €13.34 (Significantly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Axogen's adjusted revenue per share for the three months ended in Mar. 2026 was €1.030. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €2.90 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Axogen's average Cyclically Adjusted Revenue Growth Rate was 14.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 13.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Axogen was 15.90% per year. The lowest was -11.40% per year. And the median was 2.30% per year.

As of today (2026-07-22), Axogen's current stock price is €35.11. Axogen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €2.90. Axogen's Cyclically Adjusted PS Ratio of today is 12.11.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Axogen was 28.06. The lowest was 1.45. And the median was 6.03.


Axogen  (FRA:LT3) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Axogen's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=35.11/2.90
=12.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Axogen was 28.06. The lowest was 1.45. And the median was 6.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Axogen Cyclically Adjusted Revenue per Share Related Terms


Axogen Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Axogen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axogen Cyclically Adjusted Revenue per Share Chart

Axogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.67 2.19 2.35 2.90 2.92

Axogen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.85 2.65 2.73 2.92 2.90

FRA:LT3 vs TMDX, BFLY, ESTA: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Axogen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axogen Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Axogen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Axogen's Cyclically Adjusted PS Ratio falls into.


FRA:LT3
64GF Score
Axogen Inc FRA:LT3
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Axogen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Axogen's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.03/330.2130*330.2130
=1.030

Current CPI (Mar. 2026) = 330.2130.

Axogen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.307 241.018 0.421
201609 0.331 241.428 0.453
201612 0.332 241.432 0.454
201703 0.347 243.801 0.470
201706 0.408 244.955 0.550
201709 0.404 246.819 0.541
201712 0.424 246.524 0.568
201803 0.405 249.554 0.536
201806 0.480 251.989 0.629
201809 0.504 252.439 0.659
201812 0.531 251.233 0.698
201903 0.529 254.202 0.687
201906 0.603 256.143 0.777
201909 0.659 256.759 0.848
201912 0.642 256.974 0.825
202003 0.553 258.115 0.707
202006 0.493 257.797 0.631
202009 0.708 260.280 0.898
202012 0.664 260.474 0.842
202103 0.640 264.877 0.798
202106 0.678 271.696 0.824
202109 0.640 274.310 0.770
202112 0.671 278.802 0.795
202203 0.673 287.504 0.773
202206 0.776 296.311 0.865
202209 0.884 296.808 0.983
202212 0.807 296.797 0.898
202303 0.804 301.836 0.880
202306 0.822 305.109 0.890
202309 0.899 307.789 0.964
202312 0.914 306.746 0.984
202403 0.881 312.332 0.931
202406 1.018 314.175 1.070
202409 0.999 315.301 1.046
202412 1.021 315.605 1.068
202503 0.994 319.799 1.026
202506 1.024 322.561 1.048
202509 1.043 324.800 1.060
202512 1.101 324.054 1.122
202603 1.030 330.213 1.030

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €2.90 mean?
Axogen (FRA:LT3) has a Cyclically Adjusted Revenue per Share of €2.90 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Axogen and its competitors.
Is Axogen's Cyclically Adjusted Revenue per Share too high?
Axogen's current Cyclically Adjusted Revenue per Share is €2.90. Overall, Axogen has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Axogen's Cyclically Adjusted Revenue per Share compare to TMDX and BFLY?
Axogen's Cyclically Adjusted Revenue per Share of €2.90 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Axogen and its competitors. Axogen's current Cyclically Adjusted Revenue per Share is €2.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axogen stock overvalued right now?
Based on GuruFocus' analysis, Axogen (FRA:LT3) is currently considered Significantly Overvalued. The stock's GF Value™ is €13.34, compared to a current price of €35.11 — trading 163.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €2.90. Axogen's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Axogen (FRA:LT3), the current Cyclically Adjusted Revenue per Share is €2.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axogen (FRA:LT3) Overvalued in 2026?

Based on GuruFocus' analysis, Axogen stock appears to be overvalued. The current stock price of €35.11 is trading 163.2% above its estimated GF Value™ of €13.34. GuruFocus considers Axogen to be Significantly Overvalued.

Key valuation signals for FRA:LT3:

  • Cyclically Adjusted Revenue per Share: €2.90
  • GF Value™: €13.34 vs. price of €35.11 (163.2% above fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the FRA:LT3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Axogen Business Description

Other Exchanges AXGN:USA0HKD:UKLT3:Germany
Address 13631 Progress Boulevard, Suite 400, Alachua, FL, USA, 32615
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
64GF Score

Get the complete analysis for FRA:LT3

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€35.11
Price
€13.34
GF Value